Horm Metab Res 2007; 39(10): 726-729
DOI: 10.1055/s-2007-990273
Review

© Georg Thieme Verlag KG Stuttgart · New York

Contribution of Triglyceride-rich Lipoproteins to Plasma Free Fatty Acids

J. M. Miles 1 , R. H. Nelson 1
  • 1Endocrine Research Unit, Mayo Clinic, Rochester, MN, USA
Further Information

Publication History

received 16.10.2006

accepted 18.06.2007

Publication Date:
22 October 2007 (online)

Abstract

Free fatty acids are the major lipid fuel of the body. Dysregulation of adipose tissue lipolysis results in increased plasma free fatty acid concentrations, and via that mechanism contributes to insulin resistance in obesity and type 2 diabetes mellitus. Adipose tissue hormone sensitive lipase is thought to be responsible for the production of the majority of free fatty acids. However, a separate contribution comes from the action of endothelial lipases, especially lipoprotein lipase, on triglyceride-rich lipoproteins via a process known as spillover. The primary substrate for spillover appears to be chylomicrons derived from dietary fat. The spillover of fatty acids into the free fatty acid pool varies from one tissue to another. For example, spillover is low (∼14%) in the forearm of healthy volunteers, suggesting that triglyceride fatty acid storage is relatively efficient in skeletal muscle. In contrast, spillover appears to be higher in adipose tissue and may also be higher in the splanchnic bed, based on preliminary data. If systemic spillover is increased in insulin resistant states such as diabetes, this could represent a mechanism contributing to the abnormal increases in plasma concentrations of free fatty acids in that condition.

References

  • 1 Coppack SW, Jensen MD, Miles JM. The in vivo regulation of lipolysis in humans.  J Lipid Res. 1994;  35 177-193
  • 2 Basso LV, Havel RJ. Hepatic metabolism of free fatty acids in normal and diabetic dogs.  J Clin Invest. 1970;  49 537-547
  • 3 Gold M, Spitzer JJ. Metabolism of free fatty acids by myocardium and kidney.  Am J Physiol. 1964;  206 153-158
  • 4 Wisneski JA, Gertz EW, Neese RA, Mayr M. Myocardial metabolism of free fatty acids. Studies with 14C-labelled substrates in humans.  J Clin Invest. 1987;  79 359-366
  • 5 Andres R, Cader G, Zierler KL. The quantitatively minor role of carbohydrate in oxidative metabolism by skeletal muscle in intact man in the basal state: measurements of oxygen and glucose uptake and carbon dioxide and lactate production in the forearm.  J Clin Invest. 1956;  35 671-682
  • 6 Miles JM, Jensen MD. Counterpoint: visceral adiposity is not causally related to insulin resistance.  Diabetes Care. 2005;  28 2326-2328
  • 7 Boden G, Jadali F, White J, Liang Y, Mozzoli M, Chen X, Coleman E, Smith C. Effects of fat on insulin stimulated carbohydrate metabolism in normal men.  J Clin Invest. 1991;  88 960-966
  • 8 Stojiljkovic MP, Zhang D, Lopes HF, Lee CG, Goodfriend TL, Egan BM. Hemodynamic effects of lipids in humans.  Am J Physiol. 2001;  280 R1674-R1679
  • 9 Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation.  J Clin Invest. 1997;  100 1230-1239
  • 10 Frayn KN, Coppack SW. Insulin resistance, adipose tissue and coronary heart disease.  Clin Sci. 1992;  82 1-8
  • 11 Eckel RH. Lipoprotein lipase: a multifunctional enzyme relevant to common metabolic diseases.  N Engl J Med. 1989;  320 1060-1068
  • 12 Olivecrona T. Metabolism of chylomicrons labeled with C14-glycerol-H3-palmitic acid in the rat.  J Lipid Res. 1962;  3 439-444
  • 13 Bergman EN, Havel RJ, Wolfe BM, Bohmer T. Quantitative studies of the metabolism of chylomicron triglycerides and cholesterol by liver and extrahepatic tissues of sheep and dogs.  J Clin Invest. 1971;  50 1831
  • 14 Miles J, Park Y, Walewicz D, Russell-Lopez C, Windsor S, Isley W, Coppack S, Harris W. Systemic and forearm triglyceride metabolism: fate of lipoprotein lipase-generated glycerol and free fatty acids.  Diabetes. 2004;  53 521-527
  • 15 Gormsen LC, Jensen MD, Nielsen S. Measuring VLDL-triglyceride turnover in humans using ex vivo-prepared VLDL tracer.  J Lipid Res. 2006;  47 99-106
  • 16 Wolfe RR, Shaw JHF, Durkot MJ. Effects of sepsis on VLDL kinetics: responses in basal state and during glucose infusion.  Am J Physiol. 1985;  248 E732-E740
  • 17 Mittendorfer B, Liem O, Patterson BW, Miles JM, Klein S. What does the measurement of whole-body fatty acid rate of appearance in plasma by using a fatty acid tracer really mean?.  Diabetes. 2003;  52 1641-1648
  • 18 Miles JM, Wooldridge D, Grellner WJ, Windsor S, Isley WL, Klein S, Harris WS. Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: effects of insulin sensitization therapy.  Diabetes. 2003;  52 675-681
  • 19 Park Y, Grellner WJ, Harris WS, Miles JM. A new method for the study of chylomicron kinetics in vivo.  Am J Physiol. 2000;  279 E1258-E1263
  • 20 Iriyama K, Nishiwaki H, Terashima H, Tonouchi H, Miki C, Suzuki H, Carpentier Y. Apolipoprotein C-II modifications associated with an infusion of artificial lipid particles.  JPEN. 1988;  12 60-62
  • 21 Coppack SW, Fisher RM, Gibbons GF, Humphreys SM, MacDonough MJ, Potts JL, Frayn KN. Postprandial substrate deposition in human forearm and adipose tissues in vivo.  Clin Sci. 1990;  79 339-348
  • 22 Evans K, Burdge GC, Wootton SA, Clark ML, Frayn KN. Regulation of dietary fatty acid entrapment in subcutaneous adipose tissue and skeletal muscle.  Diabetes. 2002;  51 2684-2690
  • 23 Nelson RH, Edgerton DS, Basu R, Roesner JC, Cherrington AD, Miles JM. Triglyceride uptake and lipoprotein lipase - generated fatty acid spillover in the splanchnic bed of dogs.  Diabetes. 2007;  56 1850-1855
  • 24 Karpe F, Humphreys S, Samra J, Summers L, Frayn K. Clearance of lipoprotein remnant particles in adipose tissue and muscle in humans.  J Lipid Res. 1997;  38 2335-2343
  • 25 Jensen MD, Cardin S, Edgerton D, Cherrington A. Splanchnic free fatty acid kinetics.  Am J Physiol. 2003;  284 E1140-E1148
  • 26 Park Y, Damron BD, Miles JM, Harris WS. Measurement of human chylomicron triglyceride clearance with a labeled commercial lipid emulsion.  Lipids. 2001;  36 115-120
  • 27 Sprecher DL, Knauer SL, Black DM, Kaplan LA, Akeson AA, Dusing M, Lattier D, Stein EA, Rymaszewski M, Wiginton DA. Chylomicron-retinyl palmitate clearance in type I hyperlipidemic families.  J Clin Invest. 1991;  88 985-994
  • 28 Levak-Frank S, Hofmann W, Weinstock PH, Radner H, Sattler W, Breslow JL, Zechner R. Induced mutant mouse lines that express lipoprotein lipase in cardiac muscle, but not in skeletal muscle and adipose tissue, have normal plasma triglyceride and high-density lipoprotein-cholesterol levels.  Proc Natl Acad Sci USA. 1999;  96 3165-3170
  • 29 Augustus AS, Kako Y, Yagyu H, Goldberg IJ. Routes of FA delivery to cardiac muscle: modulation of lipoprotein lipolysis alters uptake of TG-derived FA.  Am J Physiol. 2003;  284 E331-E339
  • 30 Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, Gropler RJ. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women.  Circulation. 2004;  109 2191-2196 , Epub 2004 May 21
  • 31 Nelson RH, Prasad A, Lerman A, Miles JM. Myocardial uptake of circulating triglycerides in nondiabetic patients with heart disease.  Diabetes. 2007;  56 527-530
  • 32 Roust LR, Jensen MD. Postprandial free fatty acid kinetics are abnormal in upper body obesity.  Diabetes. 1993;  42 1567-1573

Correspondence

J. M. MilesMD 

Endocrine Research Unit

Mayo Clinic

Rochester

55905 MN

USA

Phone: +1/507/284 56 43

Fax: +1/507/255 48 28

Email: miles.john@mayo.edu

    >